INTERACTIVE VISUAL AID 
TYPE 2 DIABETES

For both HCPs and their patients, the treatment of type 2 diabetes has been accompanied by a very real sense of frustration. HCPs are frustrated that patients lack the motivation to do what they need to do to maintain their treatment. Patients are frustrated that their best efforts are not successful. Poor outcomes lead to further noncompliance, which leads to less engagement and even discontinuation of treatment.

BYDUREON breaks this cycle of failure. HCPs can take command of the chaos of their patients’ type 2 diabetes and provide lasting success. Patients feel that this is a therapy that fits into their life and that BYDUREON works with them to control their diabetes, instead of having their diabetes control them. Some patients, for the first time since their diagnosis, feel that this is a regimen they can actually follow. In turn, the continuous presence of exenatide delivers significant therapeutic benefits, enabling patients to reach treatment goals and achieve glycaemic control.

The updated MVA allows sales professionals to bring the BYDUREON story to life via the inclusion of visually dynamic patient profiles, more robust efficacy, and safety data to establish it as the injectable of choice.